Related Experiment Videos
Phenotypic changes associated with DYNACTIN-2 (DCTN2) over expression characterise SJSA-1 osteosarcoma cells
Kieran L Bransfield1, Jon M Askham, Jack P Leek
1Molecular Medicine Unit, The University of Leeds, St. James's University Hospital, Leeds, United Kingdom.
Molecular Carcinogenesis
|December 22, 2005
Summary
Persistent DYNACTIN-2 (DCTN2) overexpression in cancer cells causes cellular changes but does not appear to drive carcinogenesis. Further studies are needed to confirm this finding in cancer development.
Area of Science:
- Oncology
- Cell Biology
- Genetics
Background:
- DYNACTIN-2 (DCTN2) is located on chromosome 12q13-q15, a region amplified in various cancers.
- Transient DCTN2 overexpression disrupts the DYNEIN-dynactin motor, affecting cellular processes like cargo transport, centrosome function, and mitosis, potentially predisposing cells to cancer.
Purpose of the Study:
- To investigate the role of DCTN2 genomic amplification and sustained overexpression in cancer cells.
- To determine if DCTN2 overexpression contributes to carcinogenesis.
Main Methods:
- Quantitative fluorescent multiplex PCR (QFMPCR) to analyze chromosome 12q13-q15 amplicons in cancer cell lines.
- Western blot analysis to assess DCTN2 protein levels.
- Microscopy to evaluate DCTN2 immunofluorescence, centrosome, and Golgi marker localization.
Main Results:
- DCTN2 amplification was detected in SJSA-1, U373MG, and SJRH30 cells.
- Sustained DCTN2 overexpression was observed only in SJSA-1 cells.
- SJSA-1 cells exhibited altered DCTN2 immunofluorescence and diminished centrosome/Golgi marker focus, yet showed unimpaired TP53 nuclear transport and were easily propagated.
Conclusions:
- Persistent DCTN2 overexpression is tolerated in SJSA-1 cancer cells despite predicted phenotypic abnormalities.
- This preliminary study suggests DCTN2 overexpression may not play a major role in carcinogenesis.
- Further research is required to definitively establish the role of DCTN2 in cancer development.